Easywell Biomedicals, Inc. (TPEX:1799)

Market Cap	4.84B -41.3%
Revenue (ttm)	597.41M +10.5%
Net Income	-73.14M
EPS	-0.59
Shares Out	124.69M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	163,609
Average Volume	252,106
Open	38.10
Previous Close	37.60
Day's Range	38.00 - 39.40
52-Week Range	27.65 - 77.00
Beta	0.07
RSI	60.80
Earnings Date	Mar 27, 2026

About Easywell Biomedicals

Easywell Biomedicals, Inc., together with its subsidiaries, develops, manufactures, and sells active pharmaceutical ingredients and over-the-counter drug products in America. It operates through Drug Development and Other segments. The company develops TLX-001, an anti-cough medicine; TLX-005, an anti-urinary incontinence medicine; TLX-006 for treatment of breast cancer in PMS women; TLX-007 and TLX-004, an anti-depressant; TLX-008 for prevention of pneumocystis pneumonia; TLX-012 for treatment of epilepsy; TLX-017 for treatment of chronic angi...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1998
• Country: Taiwan
• Stock Exchange: Taipei Exchange
• Ticker Symbol: 1799

Financial Performance

In 2025, Easywell Biomedicals's revenue was 597.41 million, an increase of 10.54% compared to the previous year's 540.44 million. Losses were -73.14 million, -24.96% less than in 2024.